Content uploaded by Kevin McKernan
Author content
All content in this area was uploaded by Kevin McKernan on Sep 02, 2023
Content may be subject to copyright.
Sequencing of bivalent Moderna and Pzer mRNA vaccines reveals nanogram to microgram
quanes of expression vector dsDNA per dose
!"#$%&'
(%)**+*
,-./01(*(
(233, //#3, /4567%1)5
)%801)+9
1%:91;66<3=81<3
%*/01>/#3, /%
)/01801*/01(/080
>())%*209#
/01(**801)+
)**801801))
4)), /%>801)
2ntroducon
**/01>
:$??@???@ ??6;*
%*0#%:A;/01*0et al
/01%).801--E.coli
in-vitroB%%*/01:0??;=
801C)*>
-/019166<*801/01:D??##
&;=81*<:#=(?&;
/C801%2*)
*801):E#(???;
Results
)*801(%3
(F-%0(9
$/01#3*3*/01)'G
*)801:=?;/01#3
%1%0et al
/01(/013%801
H>*%>801*
(%1:=6;
().)+3, //#3, /%
>3/01801()
*)3%801:=6;%*,-.
B?)%*,-.?>(
*I!.):8&&&;
:&J;
Figure 11%*/01#3%(>:;%
:;%1/%*
:%(;
Figure 2,*.%*/01#3%1(9$<= >
:;*:%(;0<:;=
:%(;I!:%((;
Figure 3/0(3(2:/0#3/01#
3;,-.*:K;?:;B?FI!
:);3, /%>>
L/03M)9!
.),%%)3F*
%1:>%3)*;B?
Figure 4*,-.,-.?B?
)
Figure 5A )*2)I(:2I;
*B?),-.?K2I(
.#((>(K2I((
B?)
B?(F(%E/2I(
N,O(*%*B?
?0#22I)3I
)2II?(2I(.(*
2I
(,-.-.%%
((+2(%.*
%*
(%(*B?3%.
3:';2(%#
%B?
H*%*B?(*
(%B?
='1%(B?3
%()**%
:='$;
Figure5B.2I(*,?P>!P?6(B?
:;9),?P>!P?6*?*B?
333(
(,-.?
,-.)?%B?I!9
(+.)))
()**
).*801-(1
)5801:801;/01:)%/01;
1)5B'#6<Q*801?6B#
''&<Q*/016Q4567%)#?J<Q
*801?J#'?J<Q*/01*)801
/01)6:<Q;
:?<Q;)*%801/01)*
/01%(+
Figure 61)5?6B<QR''&<Q*/01
:K;B'#6<Q801)5H801
(>)**#>(
*0#%/01801%(0#
%/01%)%>>
.*>/01K+%
*0%%
)*801
4)), /%(28,4K()
>()(,-.>3
3O*)(3, //#3, /*
3, /%-801(/#3, /-801/01
3, /().+)((*
%)*/#3, /, /:, /(;
Figure 73, /*,-.O((802:K;/01:;
E/013 *>I%+I
802)>)/01%)%*
802%801/01O3, /
Figure 8/#3, /-801/01( F
(,-.>I%:K$;)B
%.)/01>#? K
(802+*8013)*
/#, //0:/;( FO801
Figure 9. Q*,-.Q*%F*J
*?!*I>3, /:K;1%
'Q*:/;
Figure 10Q*,-.Q*%F*J
*??*I>/#3, /:K;1%
'Q*:/;
Figure 11Q*+F *>
:K;(3, /+*%
3 ,-.O3*)(
(?>(,-.
*%'Q*
/01:/;
Figure 12.Q*+F *>
:K;(/#3, / K(>I
>)3, /(' F#
Q*:/;
Table 1456=%)!#?J<Q*801?J#
'?J<Q*/01
%)(%.(28/#3, />
*801)*3)
801.1+(801
))4567%1)52
(O))
(3))*/01()3%801#
3, /%
Figure 13.($>(%.28*>L)
/#3, /%#*)(
(*801(*?*(*> *
S?T'*</#3, /)%<J*801
)'*<Q*!<Q*8011%801
802.*%3)(
(3)802456
1)5
(>(*%)J,-.(
3, //#3, /
Figure 14,-.$:;J,-./01
(+):$M;
Figure 15Q*Q**%F(C3, /:K;/#
3, /:;*I:;>:;J(
Table 2. *>I3, /:801%;)*
.%>*)*
)%/8 :I > ;)*>I
801T
Table 3. *>I/#3, /:/01U801;/)*/01V801
*!6V"V91(66VJ#B*91
Discussion
)*801)
H4561)5F
3)-)*91
*66801</013, //#3, /-)/01801)1#?
F(>I/#3, /V66
):?W"T6;2( F:'#B ;
(>3, //#3, /(2456
1801)(3, /%-
(802(*%3, /
*(4561(*%
%"!%802((
(3, /)801*
4561)5
3, /X%)801(
*%Y%801)=
+("#!%) ?
:(;))*%
-.,)*
-/01()3())>
3, /
1)%4561)57)801
3)-))%>(0#%/01=
()((%
(%-*%3, //#3, /
91)
**91>)*801
/)801%801
())%*
C>E.coli801*):#=(
?&;$>E.coli801((3, / 6'
%%*1/# I#?
:Z??;(>3)%*
/01(3209#
)*/01801%1et al:1???;801
)*3>(O3209#*/
)*I!.),-.O
(**)(>*
)209#)%3801
.)*-
,3**Det al.%
3:8#9D??;(*C
).**3
+91:66<801</01;(456
1+=81:<;()
3, /(%:,;,
)*E.coliK#(,9+)
%+C):Z??;
1)*%>(*%
(%%(>/01>(
*801*)*/01
801/01%*>
3/0%3>%1*%
+))(>3801
/01)*)*3, /%%
)(%)%
>%-*80133
%/01
H3**>%
*802*
)*801H801
801%)>
)%4561%>((
7>(801/01>((0#
%-%*)%1(
F(/#3, /3, /(>3
)*91)#)3, //#3, /
%*>>))
*
Methods
Purifying the mRNA from the LNPs
LiDs/SPRI puricaon
Q*(:<6<'*;
'Q*?X8(Q*I0,
Q*X2
?66Q*1:$>;
?'Q*?' ?:0(9$;
()+G*'*))
$(&"#(*(((?Q
*JX9L(K%*6Q*??Q*
(1)5
CTAB/Chloroform/SPRI puricaon of Vaccines
%3, /*((8<,/2-)*
K3%0,-)1
1$< *<,/2)().**3, /
1$7%6Q*I('Q* 1$: )1
12I1+2,-)>[!?!;(+*'
6B\ JQ**(+&*6
?'Q*3(?'Q*)$
*)F(+*'
)%(((BX9
()(-%6Q* )F
Simple boil preparaon for evaluang vaccine qPCR.
%>#Q*, /)
*%F:!??J;
"'\ *"
&'\ *?
Library Construcon for Sequencing
'Q*Q(/01#3*23
09$09$0+E228)/01%*2:09$[9BB";
**))(*'
=%)(+!?\ '
)
0/),%1(*
**%%(-*"%
*1)%)(
*/013%911
/01:]'X; /01
K)9218)8013F
*))(%&&&&XD2
(%%((**(
RNase A treatment of the Vaccines
/01%0#%>(/01#
L/01(%()+/01
%801*3I/01(%3
(6B\ *6(Q*?E<Q/0
1*09$/0)(-'G*12I1+:
[!?;(?Q?K801-)'Q(*801
3
DNase treatment of the vaccines
'Q* 1$-(6B\ *6(?Q802"Q*
802F:* [!?!6;?'Q*8%F(
80)/)(-"QX2!Q1'Q
?)()+)K*')%
(((JX9L
Whole genome shotgun of RNase’d Vaccines.
'Q*801(3%H>
H%)>>**801.
>*Y
Qubit™ 3 Fluorometry
4567%(*$1$/01$/>:[6B6;
$1)%8014)):[6"";
*)
E.coli qPCR
,99598)%:[!??;().
*)
qPCR and RT-qPCR Spike Assay
#P,-.PDPI+#>P=(
]11 1 1
#P,-.PDPI+#>P/
] 1 1
#P,-.PDPI+#>P,
]<'"#=1< 111 1<Z90<11 1 11<621$>=4<
qPCR and RT-qPCR Vector Origin Assay
PI+#PLP=(
] 1 11 11
PI+#PLP/
1 11 1
PI+#PLP,
<'9G<111 1 1<Z90< 1 1 <621$>=4<
928)
Make 50X primer-probe mix.
?'Q=(,
? ?'Q/,
6 ?'Q,
! 6B'Q*?
E'Q*+qPCR master mix(:'Q<
);
EQ*+RT-qPCR master mix(
Medicinal Genomics Master Mix kits used
MV<<<3, /###6#?#+
? MV<<<>##3##>
Reacon setup for 30 reacons of qPCR
!Q9.%+:;
?!Q/)$F:;
?!"Q*?
'Q*,#,>
'Q*,#,L
E6JQ*+'Q*-:QI+801</01U!Q?*
^';
Reacon setup for 34 reacons of RT-qPCR
?Q9.%+
&"Q*?
?Q/02:;
!Q8:;
Q,#,>
Q,#,L
Q*+Q*I+801</01
Medicinal Genomics MIP DNA Puricaon Kit used
MV<<<12I1+#801#9+)##?#)P?
1$< *<,/2801</01)
Cycling condions
)(>*3, //#3, /0V'\ />(
3, / 3, /+>.%(F%
'\ =>*/01801(3, //#3, /
%((/*
% )*3, //#3, /
3**$>,) LT">T!
L
>
Sequencing Data
Raw Illumina Reads RNA-seq
,-.$I=(
,-.$I/
,-.$I?=(
,-.$I?/
I=(
I/
I?=(
I?/
/-?'":;81>
?'"*-L,P/9E/0*2**
-O)-(
,-.I=(
,-.I/
,-.I?=(
,-.I?/
I=(
I/
I?=(
I?/
Megahit Assemblies
,-.I
,-.I?
I
I?
Illumina Reads mapped back to Megahit Assemblies
,-.I$1= 2+=
,-.I?$1= 2+=
I$1= 2+=
I?$1= 2+=
Q30 Filtered Illumina Reads (use these for transcriponal error rate esmates)
=4#=(V]*3#-##*3*3
,-.I=(/
,-.I//
,-.I?=(/
,-.I?//
I=(/
I//
I?=(/
I?//
Q30 BAM les. Q30 Reads mapped against Megahit assemblies
,-.I36#$1- 2+=
,-.I?36#$1- 2+=
I36#$1- 2+=
I?36#$1- 2+=
IGVtools error by base on q30 reads
=T,)),):U;1U UUU0U8)U2)0)
#1# ###0#8)#2)
I
I?
,-.I
,-.I?
Analysis pipeline
/()+(
#/23
#)
*1/# I#?
#$1-*(2I
)
$H1# #>*
K(#:(((;#E.+
2I #2I(.23
RNase Treated Libraries-BAM les
)-$1-(
(#)P#L$1])@+)@
)%
*P-+_`a#b<<<b_@>#cdP-+e##
@*)_(#cdP-+eabWf4ba#*?a#
b<0gV<<b_@b0()*cd)e<cP-+b@c
dP-+ec)]cdP-+e##<cd)e##+@@
,P/0PHP>!PB*
,P/0PHP>!PB
,P/0PHP>!PB
,?P/0PHP>!P?6*
,?P/0PHP>!P?6
,?P/0PHP>!P?6
Author contribuons
D# 33, /%4561
)5*%K
#L).801))53, /
#)+%)
Con@icts of interest- 1*%*(
**3, /801)>%
Acknowledgements.
HO>>Z*.3HO>>
D/.D>>%>,)%I)$M%
=%%8H,**
/*
1L*==8$ /8???
2/)*,-.$0 LI28#&/01I
$0"??2I Curr Issues Mol Biol44V'#?"
$,=, F%$$/>??
h9V )9+( LI28>,12%$0"??
:,-.#$0;I)8*1)V10
*21))%/01IJ Immunol207V?!'#?!
D1EI(8H0$>D,H
??61/# I#?>/013?J%
K LI28#&)APMIS131V?J#6?
8#9D1)L>2%1(=`0,>$>
$MM$%/`??1*)1/#
I?#>#/013*$0#"??/01#?B6
GitHub
8818$ &&&33*
Exp Cell Res253VB6#B??
0F#81G.8C $$.90%>1???
8)*/01 LI28#&I$>JAMA Pediatr
176V?"J#?B
D=??##&/O//(Commi2ee for
Medicinal Products for Human Use EMEA/H/C/005735/RR
,/H%%>$9M/, ,&JI!B?
>F+I!
Nucleic acids research9V"!B#""J
08D??-)9%V/*0#%
LI28#&IACS Cent Sci7VB!J#B'"
#=((1D,?&2(#
801Biologicals37V&#&'
E#(D89/Li 1 >91=8???202/3
)8) *801I2)*%2 #
81)%/Front Immunol13VJ"B
Z/1$2/1D/??/#
1/# I#?/01*
+)#)Proceedings of the Naonal Academy of Sciences
of the United States of America118
Z4HZGGZ /GZ$Z??(
+9#11I#
Mol Ther Methods Clin Dev22V?&6#66
